Iovance Biotherapeutics, Inc.
IOVANASDAQHealthcare● Active
$4.06
$-0.17(-4.05%)
Market Cap$1.5B
P/E Ratio—
52W High$5.63
52W Low$1.66
Iovance Biotherapeutics, Inc. (IOVA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IOVA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.19
Est. -$0.19 · +0.0%
Revenue
$0.07B
Est. $0.08B · -8.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss Revenue✓ 3-Quarter EPS Beat Streak
IOVA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.17 | — | — | — | $0.09B | — |
| — Q2 FY2026 | May 7, 2026 | -$0.19 | -$0.19 | +0.0% | $0.07B | $0.08B | -8.2% |
| ▲ Q1 FY2026 | Feb 24, 2026 | -$0.22 | -$0.18 | +18.2% | $0.09B | $0.08B | +7.4% |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.29 | -$0.25 | +13.8% | $0.07B | $0.08B | -17.9% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.29 | -$0.33 | -13.8% | $0.06B | $0.08B | -23.4% |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.25 | -$0.36 | -44.0% | $0.05B | $0.08B | -40.1% |
| — Q1 FY2025 | Feb 27, 2025 | -$0.26 | -$0.26 | +0.0% | $0.07B | $0.07B | +2.1% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.31 | -$0.28 | +9.7% | $0.06B | $0.07B | -18.2% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.17
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026
EPS Actual
-$0.19
EPS Est.
-$0.19
EPS Surpr.
+0.0%
Revenue
$0.07B
Q1 FY2026
Feb 24, 2026Beat
EPS Actual
-$0.18
EPS Est.
-$0.22
EPS Surpr.
+18.2%
Revenue
$0.09B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.25
EPS Est.
-$0.29
EPS Surpr.
+13.8%
Revenue
$0.07B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.33
EPS Est.
-$0.29
EPS Surpr.
-13.8%
Revenue
$0.06B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.36
EPS Est.
-$0.25
EPS Surpr.
-44.0%
Revenue
$0.05B
Q1 FY2025
Feb 27, 2025
EPS Actual
-$0.26
EPS Est.
-$0.26
EPS Surpr.
+0.0%
Revenue
$0.07B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.28
EPS Est.
-$0.31
EPS Surpr.
+9.7%
Revenue
$0.06B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q3 FY2027 | $-0.07 | $-0.06 | $-0.06 | 1 |
| Q2 FY2027 | $-0.10 | $-0.09 | $-0.09 | 1 |
| Q1 FY2027 | $-0.11 | $-0.10 | $-0.10 | 1 |
| Q4 FY2026 | $-0.12 | $-0.11 | $-0.11 | 1 |
| Q3 FY2026 | $-0.13 | $-0.12 | $-0.11 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +0.0% | $4.09 | $3.55 | -13.20% |
| ▲ Q1 FY2026 | Feb 24, 2026 | +18.2% | $2.89 | $3.78 | +30.80% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +13.8% | $1.81 | $2.31 | +27.62% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -13.8% | $2.58 | $2.64 | +2.33% |
| ▼ Q2 FY2025 | May 8, 2025 | -44.0% | $3.13 | $3.17 | +1.28% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +0.0% | $5.35 | $5.26 | -1.68% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +9.7% | $12.14 | $12.28 | +1.15% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +8.1% | $7.33 | $7.94 | +8.32% |
Q2 FY2026-13.20%
Report Date
May 7, 2026
EPS Beat/Miss
+0.0%
Price Before
$4.09
Price After
$3.55
Q1 FY2026+30.80%
Report Date
Feb 24, 2026
EPS Beat/Miss
+18.2%
Price Before
$2.89
Price After
$3.78
Q4 FY2025+27.62%
Report Date
Nov 6, 2025
EPS Beat/Miss
+13.8%
Price Before
$1.81
Price After
$2.31
Q3 FY2025+2.33%
Report Date
Aug 7, 2025
EPS Beat/Miss
-13.8%
Price Before
$2.58
Price After
$2.64
Q2 FY2025+1.28%
Report Date
May 8, 2025
EPS Beat/Miss
-44.0%
Price Before
$3.13
Price After
$3.17
Q1 FY2025-1.68%
Report Date
Feb 27, 2025
EPS Beat/Miss
+0.0%
Price Before
$5.35
Price After
$5.26
Q4 FY2024+1.15%
Report Date
Nov 7, 2024
EPS Beat/Miss
+9.7%
Price Before
$12.14
Price After
$12.28
Q3 FY2024+8.32%
Report Date
Aug 8, 2024
EPS Beat/Miss
+8.1%
Price Before
$7.33
Price After
$7.94
Avg Beat Reaction+8.83%
Avg Miss Reaction+1.81%
Beat Rate6 / 8 quarters
Largest Move+30.80% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IOVA ends December
Iovance Biotherapeutics, Inc. (IOVA) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.19 (in line with the analyst consensus of $-0.19). IOVA has beaten EPS estimates for 3 consecutive quarters. The next IOVA earnings date is expected around September 1, 2026.
Each quarter, investors track IOVA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IOVA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IOVA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IOVA earnings · 4 questionsIovance Biotherapeutics, Inc.'s next earnings report is expected around September 1, 2026. IOVA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IOVA historically reports after market close (AMC).
IOVA earnings datewhen is IOVA earningsIOVA next earnings datewhen does IOVA report earningsIOVA earnings calendar
▸ Source: FMP · Iovance Biotherapeutics, Inc. SEC filings · US GAAP · Iovance Biotherapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026